Janus-I Science Inc.

Janus-I Science Inc. Mission

Janus-I Science Inc. has a vision and a path to create an integrated product that fundamentally changes the diagnosis and treatment of pre-symptomatic and febrile phases of infectious disease.

We combine cutting edge analytical technologies with advances in biology, nanopore sequencing and algorithmic learning to create high-value assays for healthcare, infectious disease identification, biosecurity, intelligence, and other national security needs. Our processes are designed to be implemented on multiple automation platforms, including high-throughput laboratory, near-patient, and field-forward systems.

CUSTOMERS

Our products will support the US defense, intelligence communities, and health security agencies, global health organizations, pharma partners, hospitals, clinics, physicians and patients.

EXPERIENCE

Leveraging over 100 years of combined experience in the biotechnology, diagnostics, and drug discovery industries, our scientific leadership team has developed advanced technologies for multiple government agencies and global health organizations.

NEW TECHNOLOGIES

We are committed to delivering new technologies to support the missions of our government partners and plan to commercialize these technologies in collaboration with industry-leading therapeutic, diagnostic, and research product companies.

Company

Our team is passionate to enable new capabilities for national security and healthcare.

Careers

Our work environment is challenging, motivating, rewarding and designed to foster innovation and scientific excellence

Contact

For any enquiries regarding our products & services

Specimen preparation

To create truly comprehensive sample-to-result assays, preparation of adequate volumes of clinical and environmental samples must be processed to extract and purify nucleic acids

Direct analysis of NP swabs for viruses, bacteria and host biomarkers

There are simply too many viruses to identify the cause of an infection with conventional diagnostic technologies in a rapid and cost-acceptable fashion.

Direct analysis of wounds for infections

Chronic wounds cause major humanitarian and economic burden in the United States.

Computational methods to identify, viruses, bacteria, host biomarkers

Near patient or field-forward devices that analyze nanopore sequence data must interpret huge volumes of data, match with databases of microbes and present results in an actionable fashion.

Differential diagnosis of origin for febrile illness using host response markers

A rapid (<1 hr) point of care diagnostic test that accurately classifies the causative agent generating fever would reduce healthcare costs and save lives.

Nanopore sequencing

We believe that inexpensive nanopore sequencing will change the landscape of molecular diagnostics by enabling comprehensive analysis of clinical specimens in a commercially sustainable fashion with field-deployable instrumentation.

Competitive Advantage

Janus-I Science Inc. is comprised of a team of scientists that has worked together for 20 years on contracts from government, private foundations and global health organizations. Our leadership’s initial contracts were obtained from DARPA and NIST in 1997. The leadership’s list of previous sponsors and collaborators include: DARPA, DTRA, JPEO, CDC, NIH, FDA (CFSAN), the FBI, the NIJ, Intelligence agencies, DHS, USDA, the Henry Jackson Foundation, and the Bill and Melinda Gates Foundation. Our senior leaders have also engaged with government and medical organizations in key advisory roles such as the National Preparedness and Response Science Board (NPRSB), The National Biodefense Science Board (NBSB), The DHS Biodefense Net Assessment team and the Infectious Disease Society of America (IDSA).

Technical Expertise

The Janus-I Science Inc. team has technical expertise in biology, chemistry, bioinformatics, engineering, microfluidics, drug discovery and diagnostic technology product development. A major component of the Janus-I Science value proposition is its extensive network of trusted government and company collaborative partners.